Unathi Mtengwane from Zeerust in the North West needs a compatible stem cell donor for a transplant that could save his life. However, for some patients who can’t find a compatible donor the process can be arduous, expensive, and littered with legal barriers, writes Thabo Molelekwa.
The rollout of new TB prevention medicines in South Africa has progressed slower than expected and new TB prevention guidelines have been delayed. But, reports Catherine Tomlinson, new guidelines should soon be approved and things appear to be falling into place for a faster rollout of the new medicines.
COVID began to hit South Africa badly in May 2020. Now, we are very likely beyond the worst with fewer people dying but COVID remains very infectious and rather deadly, writes Nathan Geffen and Marcus Low.
Many people in South Africa unnecessarily suffer from chronic pain due to system failures, poor access to expensive medicines, and lack of sufficient medical education on pain management. What’s worse is that even though morphine is cheap and easy to administer – those who do need palliative care often don’t receive it. Elsabé Brits takes an in-depth look at how we deal with pain in South Africa.
The South African Health Products Regulatory Authority recently approved the use of the monthly dapivirine vaginal ring for women 18 years and older to reduce the risk of HIV infection. Thabo Molelekwa looks at the evidence for the ring’s efficacy and asks what plans there are for making it available to women in South Africa.
While various medicines are produced in South Africa, the active pharmaceutical ingredients going into these medicines are mostly still imported. Catherine Tomlinson reports on a local company that is trying to change that – starting with active pharmaceutical ingredients for tuberculosis and COVID-19 medicines.
In January, Cape Town-based biotechnology company Afrigen Biologics announced that it has successfully produced a lab-scale batch of a mRNA vaccine against COVID-19 that is similar to that made by pharmaceutical company Moderna. Catherine Tomlinson takes an in-depth look at how Afrigen managed to reach this point and what further challenges have to be overcome before mRNA vaccines can be produced at scale in South Africa
Early in South Africa’s fourth COVID-19 wave, dominated by the Omicron variant, concerns were raised on what appeared to be an increase in hospitalisations among children. A few months on, Elri Voigt asks local experts what we have learnt about the Omicron variant in children.
Epinephrine auto-injectors, often known by the commercial name EpiPen, can be life-savers for people suffering severe allergic reactions, but the treatments are difficult to find in South Africa and expensive.
Unlike regulators in the United States and Europe, the South African Health Products Regulatory Authority has not yet given the green light for any form of mix-and-match COVID-19 vaccine boosting. We take a look at the regulatory issues standing in the way of people in South Africa who received the Johnson & Johnson jab being offered Pfizer boosters.
Pharmaceutical companies Merck and Pfizer recently announced early results from clinical trials showing that two new antiviral medicines are highly effective in reducing COVID-19 deaths and hospitalisation. The Medicines Patent Pool then announced licensing deals with both companies that will allow for generic versions of the two drugs to be produced. Catherine Tomlinson unpacks the licenses and asks whether generic versions of these pills might now be made in Africa.
Children living with HIV have to take multiple different antiretroviral pills or syrups twice a day, while most adults in South Africa have been offered one pill once a day regimens for around a decade. At the recent South African HIV Clinicians Society (SAHCS) conference, various speakers argued that better treatment regimens for kids are needed urgently. Thabo Molelekwa reports.
